Read more on this: https://sc.mp/11n5m
Novo Nordisk said its popular weight-loss drug Wegovy was approved in China on June 25, 2024. As the world’s second-largest economy, China is estimated to have the highest number of overweight or obese people. Novo’s shares hit record highs after the approval, but the patent on the key ingredient in Wegovy is set to expire in less than two years in China.
